Full‐active pharmaceutical ingredient nanosensitizer for augmented photoimmunotherapy by synergistic mitochondria targeting and immunogenic death inducing
Xianghui Li,
Haoran Wang,
Zhiyan Li,
Song Liu,
Yuanyuan Chen,
Zhuren Ruan,
Zhijian Yao,
Gao Wei,
Cunwei Cao,
Wenjun Zheng,
Wenxian Guan
Affiliations
Xianghui Li
Department of Dermatology and VenereologyThe First Affiliated Hospital of Guangxi Medical UniversityNanning China
Haoran Wang
State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent ManufactureNanjing University of Chinese MedicineNanjingChina
Zhiyan Li
Department of Gastrointestinal SurgeryAffiliated Nanjing Drum Tower HospitalNanjing University Medical SchoolNanjingChina
Song Liu
Department of Gastrointestinal SurgeryAffiliated Nanjing Drum Tower HospitalNanjing University Medical SchoolNanjingChina
Yuanyuan Chen
Department of Dermatology and VenereologyThe First Affiliated Hospital of Guangxi Medical UniversityNanning China
Zhuren Ruan
Department of Dermatology and VenereologyThe First Affiliated Hospital of Guangxi Medical UniversityNanning China
Zhijian Yao
Department of Dermatology and VenereologyThe First Affiliated Hospital of Guangxi Medical UniversityNanning China
Gao Wei
Department of Dermatology and VenereologyThe First Affiliated Hospital of Guangxi Medical UniversityNanning China
Cunwei Cao
Department of Dermatology and VenereologyThe First Affiliated Hospital of Guangxi Medical UniversityNanning China
Wenjun Zheng
Department of Dermatology and VenereologyThe First Affiliated Hospital of Guangxi Medical UniversityNanning China
Wenxian Guan
Department of Gastrointestinal SurgeryAffiliated Nanjing Drum Tower HospitalNanjing University Medical SchoolNanjingChina
Abstract The precise and effective activation of the immune response is crucial in promising therapy curing cancer. Photoimmunotherapy (PIT) is an emerging strategy for precise regulation and highly spatiotemporal selectivity. However, this approach faces a significant challenge due to the off‐target effect and the immunosuppressive microenvironment. To address this challenge, a nanoscale full‐active pharmaceutical ingredient (API) photo‐immune stimulator was developed. This formulation overcomes the limitations of PIT by strengthening the ability to penetrate tumors deeply and inducing precise and potent mitochondria‐targeted dual‐mode photodynamic therapy and photothermal therapy. Along with inhibiting overexpressed Hsp90, this nanosensitizer in turn improves the immunosuppressive microenvironment. Ultimately, this mitochondria‐targeted PIT demonstrated potent antitumor efficacy, achieving a remarkable inhibition rate of ≥95% for both established primary tumors and distant abscopal tumors. In conclusion, this novel self‐delivery full‐API nanosystem enhances the efficacy of phototherapy and reprograms the immunosuppressive microenvironment, thereby holding great promise in the development of precise and effective immunotherapy.